ADVFN Logo
Boards:
    Quotes:
      Boards
      News
      Market Data
      Markets
      Discover
      Subscribe Login/Register Profile Icon
      S&P 500
      5,584.54
      -0.88%
      US Tech 100
      19,659.60
      -2.28%
      Dow Jones
      39,753.75
      0.08%
      Brent Oil
      85.105
      -0.01%
      Bitcoin
      56,750.37
      -1.04%
      Registration Strip Icon for alerts Register for real-time alerts, custom portfolio, and market movers
      Get Started
      1. Home
      2. Investing
      3. Stocks
      4. USA
      5. NASDAQ
      6. TCR2 Therapeutics Inc (TCRR)

      7. TCR2 Therapeutics Inc (TCRR) News

      TCRR

      TCR2 Therapeutics (TCRR)

      TCR2 Therapeutics Inc
      		Date:
      Sort by:
       Showing the most relevant articles for your search:NASDAQ:TCRR
      DateTimeSourceHeadlineSymbolCompany
      12:21PMiHub NewswireFeaturedCannabix Technologies and Omega Laboratories Inc. Provide Positive Developments on Marijuana Breathalyzer Testing
      10/26/20216:01AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      10/25/20216:45AMGlobeNewswire Inc.TCR² Therapeutics Announces Clinical Trial Collaboration Agreement with Bristol Myers Squibb to Evaluate Gavo-cel in Combination with Opdivo® and Yervoy® in Mesothelin-Expressing Solid TumorsNASDAQ:TCRRTCR2 Therapeutics Inc
      10/22/20214:06PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      10/20/20218:17AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      10/20/20216:45AMGlobeNewswire Inc.TCR² Therapeutics Reviews Pipeline and Strategy at R&D DayNASDAQ:TCRRTCR2 Therapeutics Inc
      10/13/20216:45AMGlobeNewswire Inc.TCR² Therapeutics to Host R&D Day on October 20, 2021NASDAQ:TCRRTCR2 Therapeutics Inc
      10/05/20219:00AMGlobeNewswire Inc.TCR² Therapeutics Presents Preclinical Data on IL-15 Enhanced TRuCs at AACR Virtual Special Conference on Tumor Immunology & ImmunotherapyNASDAQ:TCRRTCR2 Therapeutics Inc
      09/17/20219:09AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      09/17/20217:30AMGlobeNewswire Inc.TCR² Therapeutics Announces Positive Interim Results from Ongoing Phase 1/2 Trial of Gavo-cel for Treatment Refractory Mesothelin-Expressing Solid TumorsNASDAQ:TCRRTCR2 Therapeutics Inc
      09/13/20216:45AMGlobeNewswire Inc.TCR2 Therapeutics to Announce Extended Results from Ongoing Phase 1/2 Trial of Gavo-cel in Mesothelin-Expressing Solid TumorsNASDAQ:TCRRTCR2 Therapeutics Inc
      09/07/20216:45AMGlobeNewswire Inc.TCR² Therapeutics to Present at the H.C. Wainwright Global Investment ConferenceNASDAQ:TCRRTCR2 Therapeutics Inc
      09/03/20214:25PMEdgar (US Regulatory)Additional Proxy Soliciting Materials (definitive) (defa14a)NASDAQ:TCRRTCR2 Therapeutics Inc
      09/02/202110:15AMDow Jones NewsTCR Therapeutics Gets FDA Orphan Designation for Gavo-cel in Bile-Duct CancerNASDAQ:TCRRTCR2 Therapeutics Inc
      09/02/20219:19AMGlobeNewswire Inc.TCR² Therapeutics Receives FDA Orphan Drug Designation for Gavo-cel for the Treatment of CholangiocarcinomaNASDAQ:TCRRTCR2 Therapeutics Inc
      08/26/20214:22PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      08/26/20217:46AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      08/26/20216:45AMGlobeNewswire Inc.TCR² Therapeutics Announces Renowned Translational Medicine Leader Priti Hegde Joins Its Board of DirectorsNASDAQ:TCRRTCR2 Therapeutics Inc
      08/17/20216:45AMGlobeNewswire Inc.TCR² Therapeutics Announces Upcoming Medical Meetings UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
      08/05/20217:17AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TCRRTCR2 Therapeutics Inc
      08/05/20217:02AMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      08/05/20216:45AMGlobeNewswire Inc.TCR² Therapeutics Reports Second Quarter 2021 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
      07/27/20215:20PMEdgar (US Regulatory)Statement of Changes in Beneficial Ownership (4)NASDAQ:TCRRTCR2 Therapeutics Inc
      07/20/20216:45AMGlobeNewswire Inc.TCR² Therapeutics Appoints Cell & Gene Therapy Manufacturing Veteran Peter Olagunju as Chief Technical OfficerNASDAQ:TCRRTCR2 Therapeutics Inc
      05/26/20216:45AMGlobeNewswire Inc.TCR² Therapeutics to Participate in Two Upcoming Conferences in JuneNASDAQ:TCRRTCR2 Therapeutics Inc
      05/13/20217:16AMEdgar (US Regulatory)Quarterly Report (10-q)NASDAQ:TCRRTCR2 Therapeutics Inc
      05/13/20216:45AMGlobeNewswire Inc.TCR² Therapeutics Reports First Quarter 2021 Financial Results and Provides Corporate UpdateNASDAQ:TCRRTCR2 Therapeutics Inc
      04/30/20214:29PMEdgar (US Regulatory)Current Report Filing (8-k)NASDAQ:TCRRTCR2 Therapeutics Inc
      04/30/20214:21PMEdgar (US Regulatory)Prospectus Filed Pursuant to Rule 424(b)(5) (424b5)NASDAQ:TCRRTCR2 Therapeutics Inc
      04/29/20216:45AMGlobeNewswire Inc.TCR² Therapeutics to Present at the Truist Securities Life Sciences SummitNASDAQ:TCRRTCR2 Therapeutics Inc
       Showing the most relevant articles for your search:NASDAQ:TCRR

      Your Recent History

      USOTC
      SYPLF
      Sanyo Special Steel (PK)
      BOV
      XPBR31
      XP
      Delayed Upgrade Clock